Binosto® – The First and Only Buffered Solution for the Treatment of Osteoporosis

Pharmaceutical Form:

Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution.

Binosto® (buffered alendronate sodium 70mg) is an easy-to-swallow, buffered oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, Binosto® has the potential to improve long-term patient compliance and adherence to therapy, thereby decreasing the risk of disabling fractures.

Indication:

Europe: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.

United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.


Binosto® Global Footprint

Binosto® is licensed in 50+ countries, commercialized in 18 countries and expected to expand to additional counties in 2019. EffRx is currently looking for Partners to commercialize Binosto® in selected European countries, Latin America and the Asia-Pacific.

Please visit www.binosto.co.uk for the EU approved prescribing information.

For Business Development inquiries please contact: info@effrx.com.

Binosto® is available by prescription in the United States to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

Visit www.binosto.com for U.S. approved prescribing information.

For more information on the Binosto® Global Footprint, click here.

Disclaimer:
Information for Healthcare professionals only. Please refer to the official prescribing information and approved indications, contraindications, and warnings in your country.